Results 51 to 60 of about 2,207,775 (300)

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

Molecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon, Peter T. Gallagher, Orly I. Richter, Neermala Poudel Neupane, Amy C. Mandigo, Jennifer J. McCann, Emanuela Dylgjeri, Irina Vasilevskaya, Christopher McNair, Channing J. Paller, Wm. Kevin Kelly, Karen E. Knudsen, Matthew J. Schiewer, Ayesha A. Shafi   +13 more
wiley   +1 more source

Technological advances in cancer immunity: from immunogenomics to single-cell analysis and artificial intelligence

Signal Transduction and Targeted Therapy, 2021
Immunotherapies play critical roles in cancer treatment. However, given that only a few patients respond to immune checkpoint blockades and other immunotherapeutic strategies, more novel technologies are needed to decipher the complicated interplay ...
Ying Xu, Guan-Hua Su, Ding Ma, Yi Xiao, Zhi-Ming Shao, Yi-Zhou Jiang   +5 more
doaj   +1 more source

Infrared laser sampling of low volumes combined with shotgun lipidomics reveals lipid markers in palatine tonsil carcinoma

Molecular Oncology, EarlyView.
Nanosecond infrared laser (NIRL) low‐volume sampling combined with shotgun lipidomics uncovers distinct lipidome alterations in oropharyngeal squamous cell carcinoma (OPSCC) of the palatine tonsil. Several lipid species consistently differentiate tumor from healthy tissue, highlighting their potential as diagnostic markers.
Leonard Kerkhoff, Manuela Moritz, Dennis Eggert, Anna Worthmann, Joerg Heeren, Henrike Zech, Till S. Clauditz, Waldemar Wilczak, Hartmut Schlüter, Christian S. Betz, Arne Böttcher, Jan Hahn   +11 more
wiley   +1 more source

Guideline for the Management Pathway and Quality Control of Breast Cancer Prevention and Treatment in China's Counties

Cancer Innovation
Breast cancer is one of the most common malignant tumors among women in China, with approximately 306,000 new cases reported in 2016. Notably, around 33% (100,400) of these cases occurred in rural areas.
Breast Cancer Expert Committee of National Cancer Quality Control Center, Cancer Prevention and Treatment Committee of Healthy China Research Center   +1 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon, Rui P. L. Neves, Nikolas H. Stoecklein, Sven‐Thorsten Liffers, Jens Siveke, Jan D. Kuhlmann, Pauline Wimberger, Paul Buderath, Rainer Kimmig, Sabine Kasimir‐Bauer   +9 more
wiley   +1 more source

Multicenter prospective study of dedicated breast positron emission tomography (dbPET) for breast cancer: examination in preoperative patients

BMC Medical Imaging
Background Dedicated breast positron emission tomography (dbPET) was developed to detect breast cancers smaller than those detectable using whole-body PET (wbPET).
Youko Satou, Yuki Nakagami, Kazuyoshi Suga, Yamaguchi Breast Cancer Study Group (YBC)   +3 more
doaj   +1 more source

Anti-cancer therapeutic strategies based on HGF/MET, EpCAM, and tumor-stromal cross talk

Cancer Cell International, 2022
As an intelligent disease, tumors apply several pathways to evade the immune system. It can use alternative routes to bypass intracellular signaling pathways, such as nuclear factor-κB (NF-κB), Wnt, and mitogen-activated protein (MAP)/phosphoinositide 3 ...
Khadijeh Barzaman, Rana Vafaei, Mitra Samadi, Mohammad Hossein Kazemi, Aysooda Hosseinzadeh, Parnaz Merikhian, Shima Moradi-Kalbolandi, Mohammad Reza Eisavand, Houra Dinvari, Leila Farahmand   +9 more
doaj   +1 more source

Prevalence of incidental breast cancer and precursor lesions in autopsy studies: A systematic review and meta-analysis [PDF]

, 2017
Background Autopsy studies demonstrate the prevalence pool of incidental breast cancer in the population, but estimates are uncertain due to small numbers in any primary study.
Barratt, Alexandra, Bell, Katy J L, Del Mar, Chris, Glasziou, Paul, Thomas, Elizabeth T, Wright, Gordon   +5 more
core   +2 more sources

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Tumor-specific MHC-II guides anthracycline exemption and immunotherapy benefit in breast cancer

Biomarker Research
Background Anthracycline-based chemotherapy, while foundational in breast cancer treatment, confers substantial cardiotoxicity. Identifying biomarkers to guide anthracycline exemption without compromising efficacy has remained an unresolved clinical ...
Zehao Wang, Yanhui Wang, Zhishuang Gao, Yue Zhou, Xiaoting Chen, Rui Xu, Yangsiyuan Zhao, Yi Zhang, Bingqiu Xiu, Jing Liu, Zhiming Shao, Shengmei Gu, Jingyan Xue, Jiong Wu   +13 more
doaj   +1 more source